ExploreWatchlistsPricing
  1. JP-listed companies
  2. SymBio Pharmaceuticals Limited
  3. Financials
  4. Effective tax rate (%)

SymBio Pharmaceuticals Limited (4582)

Market cap
¥6.6B
P/E ratio
-1.3x
Symbiopharm develops drugs for rare diseases in cancer and viral infections, focusing on compounds with proven human efficacy to reduce development risks.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndEffective tax rate (%) (Million JPY)YoY (%)
Dec 31, 2025-0.6-17.48%
Dec 31, 2024-0.7-99.31%
Dec 31, 2023-104.3-324.90%
Dec 31, 202246.4-145.02%
Dec 31, 2021-103+124979.35%
Dec 31, 2020-0.1-5.18%
Dec 31, 2019-0.1-37.20%
Dec 31, 2018-0.1+44.68%
Dec 31, 2017-0.1-41.74%
Dec 31, 2016-0.2+13.54%
Dec 31, 2015-0.1-57.79%
Dec 31, 2014-0.3

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat